Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc.NVUS · Entity 6160 | See Remarks | May 24, 2017 | May 26, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eledon Pharmaceuticals, Inc.
Report date May 24, 2017 · Filed May 26, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2027-05-23 | Direct | 52,500 |
Reported balance
After 2017-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-24 · Grant · Acquired 52,500 · Balance 52,500 F1: This option represents a right to purchase a total of 52,500 shares of the Issuer's Common Stock. 36,000 shares will vest ratably each month over three years beginning on May 24, 2017 (the "grant date"). 16,500 shares will vest on the later of achievement of a performance-related goal or the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 52,500 shares of the Issuer's Common Stock. 36,000 shares will vest ratably each month over three years beginning on May 24, 2017 (the "grant date"). 16,500 shares will vest on the later of achievement of a performance-related goal or the first anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Urovant Sciences Ltd.
Report date March 29, 2021 · Filed March 31, 2021
Section 16 reporting ended · disclosed 2021-03-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-03-29 · Disposition to issuer · Disposed 9,810 · Balance 0 F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-03-29 · Disposition to issuer · Disposed 68,971 · Balance 0 F2: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.64 · Expires 2027-11-19 | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-29 · Disposition to issuer · Disposed 133,500 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.65 · Expires 2028-10-14 | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-29 · Disposition to issuer · Disposed 3,750 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.88 · Expires 2029-01-06 | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-29 · Disposition to issuer · Disposed 70,000 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
F2: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0000899243-21-014102 · doc4.xml · derivative · entry 5 OCAMPO CHRISTINE · CIK 0001280154 · PAO; CAO/Urovant Sciences,Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 70,000 shares Expires 2029-01-06 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0000899243-21-014102 · doc4.xml · derivative · entry 4 OCAMPO CHRISTINE · CIK 0001280154 · PAO; CAO/Urovant Sciences,Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,750 shares Expires 2028-10-14 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerStock Option (Right to Buy) · Derivative | 133,500 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0000899243-21-014102 · doc4.xml · derivative · entry 3 OCAMPO CHRISTINE · CIK 0001280154 · PAO; CAO/Urovant Sciences,Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 133,500 shares Expires 2027-11-19 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerCommon Shares | 68,971 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014102 · doc4.xml · nonDerivative · entry 2 OCAMPO CHRISTINE · CIK 0001280154 · PAO; CAO/Urovant Sciences,Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. F1 · price: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerCommon Shares | 9,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014102 · doc4.xml · nonDerivative · entry 1 OCAMPO CHRISTINE · CIK 0001280154 · PAO; CAO/Urovant Sciences,Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| May 01, 2020 Filed May 4, 2020 16:53 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantCommon Shares | 44,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-026839 · doc4.xml · nonDerivative · entry 1 OCAMPO CHRISTINE · CIK 0001280154 · PAO;CAO/Urovant Sciences, Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,179 F1 · shares: 25% of the Restricted Stock Units shall vest on May 1, 2021; the remaining Restricted Stock Units vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 16:32 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantCommon Shares | 32,833 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-000882 · doc4.xml · nonDerivative · entry 1 OCAMPO CHRISTINE · CIK 0001280154 · PAO;CAO/Urovant Sciences, Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,833 F1 · shares: 25% of the Restricted Stock Units shall vest on January 7, 2021; the remaining Restricted Stock Units vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 17:22 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0000899243-19-000776 · doc4.xml · derivative · entry 1 OCAMPO CHRISTINE · CIK 0001280154 · PFAO;CAO/Urovant Sciences, Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Shares · 70,000 shares Expires 2029-01-06 F1 · derivative.exercise_date: 25% of the total shares underlying the option shall vest and become exercisable on January 2, 2020; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 18:07 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001209191-18-055410 · doc4.xml · derivative · entry 1 OCAMPO CHRISTINE · CIK 0001280154 · PFAO;CAO/Urovant Sciences,Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Shares · 3,750 shares Expires 2028-10-14 F1 · derivative.exercise_date: 25% of the total shares underlying the option shall vest and become exercisable on October 1, 2019; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| May 24, 2017 Filed May 26, 2017 20:05 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-17-014539 · doc4.xml · derivative · entry 1 OCAMPO CHRISTINE · CIK 0001280154 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2027-05-23 F1 · derivative.exercise_date: This option represents a right to purchase a total of 52,500 shares of the Issuer's Common Stock. 36,000 shares will vest ratably each month over three years beginning on May 24, 2017 (the "grant date"). 16,500 shares will vest on the later of achievement of a performance-related goal or the first anniversary of the grant date. Read SEC document |
| May 10, 2017 Filed May 12, 2017 00:30 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | PurchaseCommon Stock | 10,010 | $9.99 | $99,999.90 |
DisclosureSEC source: 0000899243-17-012930 · doc4.xml · nonDerivative · entry 1 OCAMPO CHRISTINE · CIK 0001280154 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,590 F1 · shares: All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017. F1 · balance_after: All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.